Day One

Take a look at the topics and speakers you can look forward to on day one of this year's 4th Longevity Therapeutics Summit. The agenda has been organized according to the popular hallmarks of aging, preclinical and clinical trials, novel technology in the field and investment opportunities. We have included multiple panel and roundtable discussions to give you an opportunity to ask the speakers questions, have your opinions heard and be a part of crucial debates.

8:00 am
Registration & Morning Coffee

8:50 am Chair’s Opening Remarks

Accelerating the Conversion of Biomarkers of Aging into Registrable Endpoints

9:00 am Can We Save Time in a Bottle?

  • Nir Barzilai Director , The Institute for Aging Research at the Albert Einstein College of Medicine

Synopsis

  • Discussing human genetic studies to confirm drug targets
  • Exporing biomarkers for longevity therapy
  • Considering TAME-paving the road for FDA approval of gerotherapeutics

9:30 am Utilizing Biomarker Assays to Diagnose a Variety of Neurodegenerative Diseases

Synopsis

*Virtual Talk

  • Exploring the potential of biomarker assays to revolutionize the diagnostic workup of Alzheimer’s disease
  • Assessing the future of relevant biomarkers being discovered in Parkinson’s, general neurodegeneration, and glial activation
  • Considering an overview of the latest advancements in the field of biomarkers for neurodegenerative diseases
  • Discussing directions regarding implementation of novel biomarkers in clinical practice and trials

10:00 am Molecularizing the Science of Plasma to Therapeutically Target Diseases of Aging

Synopsis

  • Discussing an integrated ’omics’ approach to identify protein drivers of health and disease in plasma to therapeutically impact trajectory of aging
  • Evaluating the clinical progress in advancing from understanding of the plasma proteome to therapeutics in age-related disorders• Discussing an integrated ’omics’ approach to identify protein drivers of health and disease in plasma to therapeutically impact trajectory of aging
  • Evaluating the clinical progress in advancing from understanding of the plasma proteome to therapeutics in age-related disorders

10:30 am
Speed Networking Break

Synopsis

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the longevity field and establish meaningful business relationships to pursue for the rest of the conference.

11:30 am Panel Discussion: The Lack of Robust Surrogate Biomarkers for Aging

  • Nir Barzilai Director , The Institute for Aging Research at the Albert Einstein College of Medicine
  • Erik Stoops Head of Development, ADx NeuroSciences
  • Viktoria Kheifets Senior Vice President , Alkahest

Synopsis

Join keynote speakers as they discuss the lack of robust biomarkers in the longevity field and methods to overcome this including:

  • Evaluating novel biomarkers that may correlate to registrable endpoints in longevity therapeutics
  • Assessing how to move novel biomarkers towards regulatory approval
  • Discussing the importance of developing defined biomarkers for aging and how we can use robust biomarkers to move the longevity field forward

The Rise of Senolytics: What is the Future of Cell Senescence in Longevity Therapeutics?

12:00 pm Highlighting Senescence-Derived Biomarkers of Aging & Osteoarthritis

  • Birgit Schilling Associate Professor Proteomics and Aging , Buck Institute for Research on Aging

Synopsis

  • Discussing the development of panels of proteins which serve as markers for aging phenotypes in order to monitor potential therapeutic interventions
  • Zooming in on senescence-derived biomarkers of aging
  • Assessing senescence markers in cartilage and bone targeting underlying mechanisms and options for intervention for osteoarthritis

12:30 pm Harnessing Endogenous Immune Biology to Ablate Pathogenic Senescent Cells & Treat Disease

Synopsis

  • Discussing therapeutically harnessing the immune system to remove senescent cells in a disease state
  • Achieving therapeutically relevant endpoints and durable effects
  • Outlining how there has been a paradigm shift for systemically treating age related multi-morbidities

1:00 pm
Lunch & Networking

Synopsis

We are proud to partner with Maxwell Biosciences who will be hosting an exclusive lunch for Longevity Experts in the field.

2:00 pm Mitochondria as Reversible Regulators of Skin Wrinkles & Hair Loss

  • Keshav K Singh, PhD Joy and Bill Harbert Endowed Chair and Professor, Heersink School of Medicine, University of Alabama at Birmingham

Synopsis

*Virtual Talk

  • Explaining how mitochondrial dysfunction leads to skin aging and loss of hair
  • Understanding how restoring mitochondrial function restores hair and mitigates skin wrinkles
  • Anayzing why mitochondria-regulated epigenetic changes play a key role in the reversal of skin aging and hair loss

2:30 pm Computational Discovery of Cellular Senescence in Age-Related Diseases to Develop Selective Senolytics

  • Marco Quarta Co-Founder & Chief Executive Officer , Rubedo Life Sciences

Synopsis

  • Discussing the definition of senescent cells as heterogeneous cell populations and considering that not all senescent cells are pathological cells
  • Assessing bioinformatic strategies that enable the discovery of senescent cell types to target in specific age-related diseases
  • Examining the development of selective novel classes of senolytics for effective pharmacological strategies to treat age-related diseases

3:00 pm Roundtable Discussion: An Evaluation of the Rise of Senolytics & the Future of Targeting Senolytic Cells

  • Birgit Schilling Associate Professor Proteomics and Aging , Buck Institute for Research on Aging
  • Robin Mansukhani Chief Executive Officer, Deciduous Therapeutics
  • Marco Quarta Co-Founder & Chief Executive Officer , Rubedo Life Sciences

Synopsis

Join your session leaders in this roundtable as they spark conversation on:

  • The sudden rise in targeting senescent cells
  • Novel clinical and preclinical trials that are progressing in the senescent space
  • Discussing whether research should be focus solely on cellular senescence or take a cocktail approach alongside other hallmarks of aging

3:30 pm
Poster Networking Session

Synopsis

Join your peers to discover the latest developments and breakthroughs, grow your network of meaningful industry connections and showcase your work to colleagues in the longevity field.

Turning Back Time with an Epigenetic Clock & Novel Preclinical & Clinical Trials that are Promoting Regeneration

4:00 pm Can Rapamycin Safely Delay or Reverse Aging Outside the Lab?

Synopsis

  • Discussing how Rapamycin is the most effective and reproducible drug for increasing lifespan and healthspan metrics in laboratory animals
  • Analyzing anecdotal data from people taking low dose rapamycin is suggestive of benefits for healthspan
  • The effects of rapamycin on age-related indications are beginning to be tested in randomized clinical trials

4:30 pm Developing Pluripotent Stem Cell-Based Therapies for the Treatment of Age-Related Diseases

  • Erin Kimbrel VP, Research , Astellas Institute for Regenerative Medicine

Synopsis

  • Examining how pluripotent stem cells (PSCs) are a key starting material for the development of off-the-shelf cell-based therapies to help treat patients with high unmet medical needs
  • Outlining the key challenges in the value chain of PSC-based therapies and discussing strategies to overcome these challenges
  • Analyzing how overcoming immunogenicity will help improve and expand the clinical application of allogeneic PSC-based therapies
  • Discussing how the marriage of gene editing technologies with PSC technology is helping to create the next generation of engineered cell therapies that go above and beyond what naturally occurring cells of a patient’s body can do

5:00 pm Using Recombinant Protein GDF11 to Promote Recovery Post Stroke

  • Mark Allen Co-Founder & Chief Executive Officer , Elevian

Synopsis

  • Exploring how GDF11 plays an important role in aging, regeneration and repair
  • Analyzing evidence that recombinant GDF11 (rGDF11) promotes recovery post stroke
  • Discussing why Elevian is sponsoring rGDF11 clinical trials to promote recovery from stroke and other aging-associated diseases

5:30 pm Examining Anti-Aging Therapies Targeting Endogenous “Retrobiome” & Immunosenescence

Synopsis

  • Discussing how aging is associated with genetic and epigenetic modulations of somatic cells accompanied with progressive immunosenescence
  • Assessing new insights into the intrinsic mechanisms of DNA damage, agerelated inflammation and immunosenescence
  • Examining approaches to their therapeutic correction with small molecules targeting LINE-1 retrotransposons and immunomodulators will be presented

6:00 pm
Chair’s Closing Remarks & End of Day One